Neuronal Ceroid Lipofuscinosis 7 via the MFSD8 Gene
Summary and Pricing
Test Method
Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture ProbesTest Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
---|---|---|---|---|---|
3811 | MFSD8 | 81479 | 81479,81479 | $990 | Order Options and Pricing |
Pricing Comments
Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.
Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
The neuronal ceroid lipofuscinoses (NCLs) are inherited neurodegenerative lysosomal storage disorders caused by the accumulation of ceroid and lipofuscin in various cell types, mainly cells of the cerebral cortex, cerebellar cortex, and retina (Dyken et al. 1988; Williams and Mole 2012). Characteristic features at onset include clumsiness; deterioration of vision and psychomotor functions; seizures and behavioral changes. Progression of clinical features results ultimately in total disability, blindness and premature death. Although NCL affects primarily children, age of onset of symptoms varies from infancy to adulthood. The incidence of NCL is variable and ranges from 1.3 to 7 per 100,000 (Mole and Williams 2013). However, it is more common in the northern European populations, particularly Finland where the incidence may reach 1 in 12,500 individuals and a carrier frequency of 1 in 70 (Rider and Rider 1988). NCLs are clinically and genetically heterogeneous. A nomenclature and classification based both on the age of onset of symptoms and the disease-causing gene has been recently developed, which classifies NCLs into thirteen subtypes (CLN1-8, 10-14) (Williams and Mole 2012). The causative gene for the CLN9 phenotype has not been identified yet (Schulz et al. 2004).
Of note, NCLs were previously known as Batten disease. However, in recent nomenclature, Batten disease only applies to NCL caused by mutations in CLN3.
CLN7 disease is characterized by late-infantile onset, usually between 2-7 years of age. It can be distinguished from the classical late-infantile CLN2 by more severe seizures and slower cerebral and cerebellar atrophy. Symptoms include ataxia, vision impairment and progressive cognitive and motor dysfunction (Kousi et al. 2009; Topcu et al. 2004).
Genetics
Most CLNs are inherited in an autosomal recessive manner. Thirteen genes have been implicated in the disorder: PPT1, TPP1, CLN3, CLN5, CLN6, MFSD8, CLN8, CTSD, DNAJC5, CTSF, ATP13A2, GRN, and KCTD7 (Mole and Williams 2013). CLN7 is caused by pathogenic variants in the MFSD8 gene (Siintola et al. 2007). To date, 35 different pathogenic variants have been reported in various ethnic populations. About half of the variants are missense. The other half is predicted to result in truncated proteins and include nonsense, splicing, small insertions or deletions, and indels. No large pathogenic deletions were reported to date (Human Gene Mutation Database). Pathogenic variants in MFSD8 account for about 40% of patients with late infantile neuronal ceroid lipofuscinosis. Most causative variants are unique to single families. A founder variant, c.881C>A (p.Thr294Lys), is common in the Roma population that originated from the former Czechoslovakia (Kousi et al. 2009; Kousi et al. 2012). The MFSD8 gene encodes the Major Facilitator Superfamily Domain-containing protein-8, a lysosomal membrane protein. It is hypothesized to be a lysosomal transporter. However, the nature of the transported substrates is unknown at this time (Siintola et al. 2007; Kousi et al. 2012).
Clinical Sensitivity - Sequencing with CNV PG-Select
Pathogenic variants in MFSD8 were identified in about 40% of patients clinically diagnosed with late infantile ceroid lipofuscinoses (Kousi et al. 2009).
Testing Strategy
This test provides full coverage of all coding exons of the MFSD8 gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.
Indications for Test
Candidates for this test are patients with a clinical diagnosis suggestive of neuronal ceroid lipofuscinosis, and late infantile onset. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in MFSD8.
Candidates for this test are patients with a clinical diagnosis suggestive of neuronal ceroid lipofuscinosis, and late infantile onset. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in MFSD8.
Gene
Official Gene Symbol | OMIM ID |
---|---|
MFSD8 | 611124 |
Inheritance | Abbreviation |
---|---|
Autosomal Dominant | AD |
Autosomal Recessive | AR |
X-Linked | XL |
Mitochondrial | MT |
Disease
Name | Inheritance | OMIM ID |
---|---|---|
Ceroid Lipofuscinosis Neuronal 7 | AR | 610951 |
Related Tests
Citations
- Dyken P.R. 1988. American journal of medical genetics. Supplement. 5: 69-84. PubMed ID: 3146331
- Human Gene Mutation Database (Bio-base).
- Kousi M. et al. 2009. Brain : a journal of neurology. 132: 810-9. PubMed ID: 19201763
- Kousi M. et al. 2012. Human mutation. 33: 42-63. PubMed ID: 21990111
- Mole S.E., Williams R.E. 2013. Neuronal Ceroid-Lipofuscinoses. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong C-T, and Stephens K, editors. GeneReviews™, Seattle (WA): University of Washington, Seattle. PubMed ID: 20301601
- Rider J.A., Rider D.L. 1988. American journal of medical genetics. Supplement. 5: 21-6. PubMed ID: 3146319
- Schulz A. et al. 2004. Annals of neurology. 56: 342-50. PubMed ID: 15349861
- Siintola E. et al. 2007. American journal of human genetics. 81: 136-46. PubMed ID: 17564970
- Topçu M. et al. 2004. The Turkish journal of pediatrics. 46: 1-10. PubMed ID: 15074367
- Williams R.E., Mole S.E. 2012. Neurology. 79: 183-91. PubMed ID: 22778232
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.